| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JHEP.2012.11.018 |
| P698 | PubMed publication ID | 23183528 |
| P50 | author | Kris V. Kowdley | Q110296712 |
| P2093 | author name string | David R Nelson | |
| John G McHutchison | |||
| Maribel Rodriguez-Torres | |||
| Michael Mader | |||
| William T Symonds | |||
| Efsevia Albanis | |||
| Eric Lawitz | |||
| Jay Lalezari | |||
| Edwin Dejesus | |||
| Deyuan Jiang | |||
| Michelle M Berrey | |||
| Christy M Hebner | |||
| Melanie T Cornpropst | |||
| P433 | issue | 4 | |
| P921 | main subject | ribavirin | Q421862 |
| sofosbuvir | Q2502747 | ||
| P304 | page(s) | 663-668 | |
| P577 | publication date | 2012-11-23 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial | |
| P478 | volume | 58 |
| Q38110693 | Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. |
| Q26773274 | Alcoholic liver disease and hepatitis C virus infection |
| Q38581352 | Alcoholic liver disease: Clinical and translational research |
| Q38244137 | An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials |
| Q40745083 | Antiviral response and resistance analysis of treatment-naïve HCV-infected patients receiving single and multiple doses of GS-9190. |
| Q64285976 | Association Between Baseline Creatinine Clearance and Treatment Failure in Patients With Hepatitis C Virus Treated With Ledipasvir and Sofosbuvir |
| Q38244931 | Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. |
| Q40735192 | Biotransformation of Daclatasvir In Vitro and in Nonclinical Species: Formation of the Main Metabolite by Pyrrolidine δ-Oxidation and Rearrangement |
| Q42201573 | Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin |
| Q26775011 | Chronic hepatitis C: This and the new era of treatment |
| Q26824075 | Chronic hepatitis C: future treatment |
| Q26998630 | Chutes and ladders in hepatitis C nucleoside drug development |
| Q38837583 | Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C. |
| Q33582596 | Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis |
| Q88457986 | Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction |
| Q26767329 | Direct anti-HCV agents |
| Q57389418 | Direct-acting antivirals for chronic hepatitis C |
| Q34557595 | Direct-acting antivirals for chronic hepatitis C. |
| Q50125681 | Drug Interchangeability of Generic and Brand Products of Fixed Dose Combination Tablets of Sofosbuvir and Ledipasvir (400/90 mg): Employment of Reference Scaled Average Bioequivalence Study on Healthy Egyptian Volunteers |
| Q57494344 | Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients |
| Q26771458 | Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis |
| Q46257659 | Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate. |
| Q41200675 | Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy |
| Q56898303 | Hepatitis C (chronic) |
| Q26775007 | Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options |
| Q26782033 | Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals |
| Q40338014 | Identification of Predictors for Treatment Failure in Hepatitis C Virus Patients Treated With Ledipasvir and Sofosbuvir |
| Q41722679 | Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. |
| Q37723620 | Initial results of efficacy and safety of Sofosbuvir among Pakistani Population: A real life trial - Hepatitis Eradication Accuracy Trial of Sofosbuvir (HEATS). |
| Q40896732 | L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. |
| Q40466129 | Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies. |
| Q42150449 | Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens |
| Q36052231 | Ledipasvir/Sofosbuvir. |
| Q34143327 | Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. |
| Q38164242 | New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. |
| Q38664453 | New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir |
| Q26800050 | New era for management of chronic hepatitis C virus using direct antiviral agents: A review |
| Q42174637 | Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations |
| Q92550189 | Pharmacokinetic Profile of a Generic Formulation of Sofosbuvir and Its Metabolite GS-331007 in Healthy Chinese Subjects |
| Q34469287 | Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir |
| Q38995024 | Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C. |
| Q88786491 | Phosphoramidates and phosphonamidates (ProTides) with antiviral activity |
| Q42235045 | Racial disparities in the proportion of current, unresolved hepatitis C virus infections in the United States, 2003-2010. |
| Q56987707 | Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression |
| Q38175491 | Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection |
| Q50262230 | Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. |
| Q33774724 | Sofosbuvir |
| Q36897890 | Sofosbuvir and ABT-450: terminator of hepatitis C virus? |
| Q41510326 | Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. |
| Q38383410 | Sofosbuvir for treatment of chronic hepatitis C. |
| Q38205737 | Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks |
| Q26827322 | Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential |
| Q38245128 | Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus |
| Q50283110 | Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection |
| Q34449397 | Sofosbuvir: A novel treatment option for chronic hepatitis C infection |
| Q26768128 | Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 |
| Q27924226 | The FDA-approved drug sofosbuvir inhibits Zika virus infection |
| Q40089234 | The ProTide Prodrug Technology: From the Concept to the Clinic |
| Q40326326 | The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. |
| Q39436509 | Treatment of hepatitis C virus infection in the future |
| Q92559474 | Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia |
| Q34571043 | Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies |
| Q38584271 | Update on the Development of Anti-Viral Agents Against Hepatitis C. |
| Q38203823 | Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations |
Search more.